Last reviewed · How we verify
Paion UK Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
5 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Morphine 6-glucuronide | Morphine 6-glucuronide | phase 3 | Opioid receptor agonist | Mu-opioid receptor (μ-OR) | Pain Management |
Therapeutic area mix
- Pain · 2
- Oncology · 1
- Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- University of Pennsylvania · 2 shared drug classes
- Albert Einstein Healthcare Network · 1 shared drug class
- Centro Medico Nacional La Raza, IMSS · 1 shared drug class
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bausch Health · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Ajenat Pharms · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Paion UK Ltd.:
- Paion UK Ltd. pipeline updates — RSS
- Paion UK Ltd. pipeline updates — Atom
- Paion UK Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Paion UK Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/paion-uk-ltd. Accessed 2026-05-16.